Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Ghilanten's preclinical anticoagulant and anti-metastatic activity does NOT establish clinical efficacy for any indication. No FDA-approved derivative exists; anti-cancer claims rest on animal models alone.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 15,000 Da
- Source species
- Haementeria ghilianii
- Discovered
- 1990 · Blankenship DT et al.
Biological Targets
- → Factor Xa
Key Citations
- Blankenship DT, Brankamp RG, Manley GD, Cardin AD (1990), Biochem Biophys Res Commun · PMID 2306252
- Brankamp RG, Manley GG, Blankenship DT, Bowlin TL, Cardin AD (1991), Blood Coagul Fibrinolysis · PMID 1772984
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.
Hirudin-PA
Hirudin variant from Hirudinaria manillensis with distinct kinetics.